Compass Pathways (NASDAQ:CMPS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a research report report published on Sunday morning,Wall Street Zen reports.

CMPS has been the subject of several other reports. Morgan Stanley lifted their price objective on Compass Pathways from $17.00 to $18.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Wells Fargo & Company lowered their target price on shares of Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. HC Wainwright lowered their target price on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.14.

Compass Pathways Stock Up 0.8%

Compass Pathways stock opened at $9.25 on Friday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -2.65 and a beta of 2.43. The stock has a fifty day simple moving average of $12.14 and a two-hundred day simple moving average of $10.43. Compass Pathways has a 12 month low of $4.88 and a 12 month high of $15.87. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Equities analysts predict that Compass Pathways will post -0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

A number of institutional investors and hedge funds have recently modified their holdings of the company. Creek Drive Management Group LLC increased its position in Compass Pathways by 91.9% during the third quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock valued at $16,520,000 after acquiring an additional 636,000 shares during the last quarter. ACT Capital Partners L.P. purchased a new stake in Compass Pathways during the third quarter valued at $567,000. Lisanti Capital Growth LLC bought a new position in Compass Pathways in the third quarter valued at about $2,468,000. Candriam S.C.A. lifted its holdings in Compass Pathways by 18.6% in the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock valued at $18,862,000 after acquiring an additional 236,417 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in Compass Pathways by 34.4% in the third quarter. Alps Advisors Inc. now owns 183,458 shares of the company’s stock valued at $2,282,000 after acquiring an additional 46,996 shares during the period. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.